CompaniesNeuroDawn Pharmaceutical

NeuroDawn Pharmaceutical

active
Nanjing, China
Founded 2020
Website
About

Small Molecules

Areas of Focus

Categories

Small Molecule PharmaceuticalChina
Clinical Trials (14)
View all

Total Trials

14

As Lead Sponsor

4

As Collaborator

10

Total Enrollment

4,546

By Phase

PHASE1/PHASE2: 1PHASE3: 3PHASE1: 6PHASE2: 4

By Status

RECRUITING: 6NOT_YET_RECRUITING: 4UNKNOWN: 2COMPLETED: 2
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
Today
NCT05836740
NCT05836766
NCT06138834
NCT07040085
Hover over trial bars to see details

Recent Trials

NCT07166380Lead Sponsor
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
PHASE1/PHASE2Not yet recruiting
18 participants
Started: Sep 20, 2025 · Completed: May 19, 2026
NCT07040085Collaborator
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
PHASE3Not yet recruiting
892 participants
Started: Aug 5, 2025 · Completed: Jun 30, 2027
NCT07055412Lead Sponsor
Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
PHASE1Not yet recruiting
24 participants
Started: Jul 10, 2025 · Completed: Dec 31, 2025
NCT07013773Collaborator
To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects
PHASE1Recruiting
20 participants
Started: May 19, 2025 · Completed: Jul 31, 2025
NCT07068841Lead Sponsor
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
PHASE1Recruiting
24 participants
Started: May 18, 2025 · Completed: Aug 30, 2025
View all 14 trials →
Locations (1)
Headquarters
Nanjing, China
Map

Loading map...